创新型疫苗加速审批上市，生物疫苗ETF(562860)有望受益

Group 1 - The China Securities Vaccine and Biotechnology Index increased by 0.36% as of April 24, 2025, with notable gains from Rongchang Bio (up 4.38%), Maiwei Bio (up 4.27%), and Qianhong Pharmaceutical (up 3.47%) [1] - The index tracks up to 50 listed companies involved in vaccine research, production, and related biotechnology sectors, reflecting the overall performance of the vaccine and biotechnology theme [1] - As of March 31, 2025, the top ten weighted stocks in the index accounted for 49.93%, including companies like Zhifei Biological, Wantai Biological, and Watson Bio [1] Group 2 - Kangfang Bio's dual antibody drug Iwosimab (PD-1/VEGF dual antibody) has once again outperformed PD-1 in head-to-head trials against Baijiahui's Trelizumab combination therapy for advanced squamous non-small cell lung cancer [2] - The head-to-head trial showed statistically significant and clinically meaningful benefits for Iwosimab combined with chemotherapy compared to Trelizumab [2] - The vaccine industry in China is expected to grow rapidly due to the implementation of new policies that promote innovation, accelerate approval processes, and encourage investment in vaccine research [2]